Bisphosphonates Are Associated With Increased Risk for Jaw Surgery in Medical Claims Data: Is it Osteonecrosis?

Journal of Oral and Maxillofacial Surgery

Volumn 64, Issue 6, 2006, Pages 917-923

  Zavras, Athanasios I ^a   Zhu, Shao ^b  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b i3 Epidemiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ADULT; ARTICLE; BONE NECROSIS; BREAST CANCER; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; HEALTH INSURANCE; HUMAN; JAW DISEASE; LUNG CANCER; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PILOT STUDY; PROSTATE CANCER; SURGICAL RISK; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; FEMALE; INSURANCE; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MALE; MANDIBLE; MAXILLA; MIDDLE AGED; ORAL DRUG ADMINISTRATION; ORAL SURGERY; OSTEOPOROSIS; PROSTATE TUMOR; RISK;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INSURANCE CLAIM REPORTING; JAW DISEASES; LUNG NEOPLASMS; MALE; MANDIBLE; MAXILLA; MIDDLE AGED; MULTIPLE MYELOMA; ORAL SURGICAL PROCEDURES; OSTEONECROSIS; OSTEOPOROSIS; PILOT PROJECTS; PROSTATIC NEOPLASMS; RISK;

EID: 33745142168     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2006.02.011     Document Type: Article

References (25)

1. Fleisch H., Rusell R.G., Bisaz S., et al. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution. Calcif Tissue Res 10 supp1 (1968) 10a
2. Little D.G., Peat R.A., McEvoy A., et al. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young wistar rats. J Bone Miner Res 18 (2003) 2016
3. Hughes D.E., MacDonald B.R., Rusell R.G., et al. Inhibition of osteoclast-like cell formation by bisphosphonates in long term cultures of human bone marrow. J Clin Invest 83 (1989) 1930
4. Sahni M., Guenther H., Fleisch H., et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91 (1993) 2004
5. Brixen K: Bisphosphonates as a potential treatment for osteogenesis imperfecta. Proceedings of the OIFE meeting, September 25-26, 1998. Vingsted, Denmark. Available at: www.brandx.net/markgash/bispho.html. Accessed February 24, 2006
6. Astrand J., and Aspenberg P. Systemic alendronate prevents resorption of necrotic bone revascularization. A bone chamber study in rats. BMC Musculoskelet Disord 3 (2002) 19
7. Gralow J. Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer. Clin Breast Cancer 5 suppl 2 (2005) S54
8. Bone H.G., Hosking D., Devogelaer J.P., et al., Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 (2004) 1189
9. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws. A growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115
10. Ruggiero S.L., Mehrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates. A review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527
11. Lugassy G., Shaham R., Nemets A., et al. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma. A new clinical entity. Am J Med 117 (2004) 440
12. Bagan J.V., Murillo J., Jimenez Y., et al. Avascular jaw osteonecrosis in association with cancer chemotherapy. Series of 10 cases. J Oral Pathol Med 34 (2005) 120
13. Migliorati C.A., Schubert M.M., Peterson D.E., et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. Cancer 104 (2005) 83
14. Schirmer I., Peters H., Reichart P.A., et al. Bisphosphonates and osteonecrosis of the jaw. Mund Kiefer Gesichtschir 9 (2005) 239
15. Durie B.G.M., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353 (2005) 99
16. Schwartz H.C. Osteonecrosis and bisphosphonates. Correlation versus causation. J Oral Maxillofac Surg 62 (2004) 763
17. Hellstein J.W., and Marek C.L. Bisphosphonate osteochemonecrosis (bis-phossy jaw). Is this phossy jaw of the 21st century?. J Oral Maxillofac Surg 63 (2005) 682
18. Woo S.B., Hande K., and Richardson P.G. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353 (2005) 100
19. Maerevoet M., Martin C., and Duck L. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353 (2005) 100
20. Melo M.D., and Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc 71 (2005) 111
21. Pamer C, McCloskey C: Postmarketing safety assessment of osteonecrosis of the jaw. Pamidronate and zoledronic acid. Available at: www.fda.gov/ohrms/dockets/ac/05/slides/2005-4095S2_03_02-FDA-Pamer.ppt. Accessed April 7, 2005
22. Summary of ONJ cases from retrospective chart review at MD Anderson Cancer Center. Novartis Pharmaceutical Corporation. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4095B2_02_07-Novart is-Zometa-App6.pdf±onj&restrict=&site=FDA&output=xml_ no_dtd&client=FDA&access=p&lr=&proxystylesheet=FDA&o e=. Accessed April 7, 2005
23. Drug linked to death of jawbone. USA Today. March 13, 2005. Available at: http://www.usatoday.com/news/health/2005-03-13-jawbone-deaths_x.htm#. Accessed April 6, 2005
24. Fournier P., Boissier S., Filleur S., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62 (2002) 6538
25. Whyte M.P., Wenkert D., Clements K.L., et al. Bisphosphonate-induced osteopetrosis. N Engl J Med 349 (2003) 457